Sun Pharmaceutical Industries Ltd. et al. v. Lupin Ltd. et al.

I'll research this case thoroughly before drafting the overview.

Case Overview and Background

The parties. This is a Hatch‑Waxman ANDA case pitting an Indian-origin specialty/generic drugmaker against an Indian-origin pure generic. Plaintiffs are Sun Pharmaceutical Industries Ltd. (Mumbai; one of India's largest pharmaceutical companies, with a U.S. specialty and generics business), its U.S. operating subsidiary Sun Pharmaceutical Industries, Inc. (Princeton/Cranbury, N.J., which markets the product through its "Sun Ophthalmics" division), and Sun Pharma Global FZE (a UAE free-zone entity that holds the BromSite/DuraSite trademark rights per the product label). The branded product at issue, BromSite® (bromfenac ophthalmic solution) 0.075%, did not originate at Sun: it was developed by Alameda, California–based InSite Vision, which Sun acquired in late 2015, and it launched in the U.S. in November 2016 as Sun's first branded U.S. product. Defendants are Lupin Ltd. (Mumbai) and its U.S. subsidiary Lupin Pharmaceuticals, Inc. (Baltimore) — a large generics manufacturer with no independent research-based pharmaceutical business relevant here, i.e., a classic ANDA defendant rather than an NPE/PAE scenario. Neither side is a university or a non-practicing entity; both are operating companies, and Sun both makes the branded drug and sells generics, so the case is a brand-vs.-generic fight inside the same industry.

The accused product and the patent. Lupin filed ANDA No. 211239 on October 25, 2017, seeking approval of a generic bromfenac ophthalmic solution 0.075% bioequivalent to BromSite, with a paragraph IV certification against the sole Orange Book patent, U.S. Patent No. 8,778,999. Sun sued within the 45-day window. The '999 patent (filed March 5, 2009; issued July 15, 2014; originally assigned to InSite Vision; inventors Hosseini, Bowman, Si and Pham; Orange Book expiry August 7, 2029) claims, in substance, a topical ophthalmic composition of bromfenac (a nonsteroidal anti-inflammatory drug approved for ophthalmic use in 2005) in a "flowable crosslinked carboxy-containing polycarbophil" mucoadhesive polymer vehicle (the DuraSite® delivery system, which extends ocular residence time), with a viscosity of about 1,000–3,400 cps and a pH of about 7.4–8.5 — ECF No. 244 at 2–3. Lupin's ANDA product matched every limitation except viscosity: its label specifies 200–400 cps, far below the claimed range, but because polycarbophil solutions are non-Newtonian and thixotropic, measured viscosity depends heavily on shear rate and spin time, making the comparison methodologically contested.

Procedural posture, venue, and significance. The case was filed February 15, 2018 in the District of New Jersey (Trenton), No. 3:18-cv-02213, before Chief Judge Freda L. Wolfson, with Magistrate Judge Tonianne J. Bongiovanni — the district that is home to Sun's U.S. business and one of the country's highest-volume ANDA venues. After a failed 2020 settlement attempt (ECF Nos. 145, 155), the court held a five-day remote bench trial in March 2021. In a 78-page opinion dated September 30, 2021 (ECF No. 244, 2021 WL 4473411), Judge Wolfson held that Lupin's ANDA did not literally infringe, that the '999 patent was obvious over Bowman I (U.S. Patent No. 6,159,458) — the inventor's own earlier polycarbophil patent, which he did not disclose to the PTO — and indefinite under Nautilus because the specification's viscosity test omitted a critical spin-time parameter; she rejected Lupin's inequitable conduct defense. The case is notable for (i) the court's holding that where a patent prescribes a test method, that method is the exclusive comparator for infringement of a non-Newtonian parameter — a ruling that collapsed the infringement and indefiniteness analyses into each other — and (ii) what happened next. Rather than appeal, Sun moved to vacate; on February 8, 2022 the court granted vacatur (ECF No. 259), the September 30 opinion was re-docketed as a "VACATED OPINION," and the parties stipulated to dismissal with prejudice on February 9, 2022 (ECF No. 261). The practical consequence is significant: a reasoned decision invalidating the patent was erased as part of a settlement, leaving the '999 patent presumptively valid and Orange Book–listed while Lupin obtained a path to market — Lupin's ANDA was approved in February 2024 (FDA approval letter for ANDA 211239), with FDA noting Lupin was the first paragraph IV filer (and flagging a possible 180-day exclusivity forfeiture for failure to obtain tentative approval within 30 months). Commercially the niche is small — IQVIA December 2023 data put bromfenac 0.075% at roughly $15 million in annual sales — but the case is a frequently cited illustration of reverse-settlement dynamics in ANDA litigation, and of how a single unclaimed measurement parameter can decide both infringement and validity.

Sourcing caveats. Party roles, patent terms, claim text and the invalidity holdings are grounded in ECF No. 244 (https://cases.justia.com/federal/district-courts/new-jersey/njdce/3:18cv02213/[366742/244](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=366742-0244)/0.pdf), the March 8, 2021 Daubert opinion (ECF No. 185), the CourtListener docket (https://www.courtlistener.com/docket/[6668689](/patent/6668689)/sun-pharmaceutical-industries-ltd-v-lupin-limited/), Law360's September 30, 2021 and February 8, 2022 reports, the FDA ANDA 211239 approval letter, and Sun's 2015 InSite acquisition and 2016 BromSite launch press releases. I could not verify the specific terms of the 2022 settlement (no public filing located), and I found no IPR petition against the '999 patent — Lupin's bromfenac IPR activity I located concerns Bausch & Lomb/Senju's Prolensa patents ('131 and '606), not the '999 patent; treat that as a negative search result rather than proof no petition exists. One secondary aggregator also lists a reissue, US RE50,218, as the current Orange Book patent for BromSite; I could not confirm that in a primary source and flag it as unverified. Docket databases list the complaint as filed February 14, 2018; the case metadata's

I'll research this case across the docket, opinions, PTAB, and trade press.

Now let me pin down the post-trial/settlement docket events and check for IPRs on the '999 patent.

Sun Pharmaceutical Industries Ltd. v. Lupin Ltd., No. 3:18-cv-02213 (D.N.J.) — Legal Developments & Outcome

Editorial note on sourcing. Docket-event detail below is drawn from the ECF-stamped documents that surfaced in search (the court's own opinions cite ECF numbers), the FDA approval letter, and trade coverage. Where I could not verify an ECF number or a date from a primary source, I say so. Two data aggregators (DrugPatentWatch, ParagraphFour) give inconsistent termination dates for this docket (2020‑02‑02/03 vs. 2021‑09‑30), which I address in the chronology.

---

1. Filing and initial pleadings

Context on the patent. The '999 patent (filed 2009-03-05, issued 2014-07-15) claims a topical ophthalmic composition of bromfenac with a "flowable crosslinked carboxy-containing polycarbophil mucoadhesive polymer," viscosity ~1,000–3,400 cps, pH ~7.4–8.5. It came to Sun via its 2015 acquisition of InSite Vision (assignment March 2016) and, with 155 days of PTA, expires 2029-08-07 — the date FDA lists in the Orange Book.

2. Pre-trial motions of substance

I found no reported motion to dismiss, motion to transfer venue, motion to stay pending IPR, or summary-judgment ruling in this action — the case was tried. The substantive pre-trial motion practice was almost entirely Daubert/expert-disqualification practice in service of the validity and inequitable-conduct theories, plus hard-fought discovery motions.

Discovery milestones of strategic significance (2019):

• Deposition discovery focused on the ANDA formulation and viscosity data — Lupin's non-infringement case rested on the ANDA's stated viscosity of 200–400 cps, versus the claim's "about 1,000 to about 3,400 cps." Lupin's 30(b)(6) designees (Dahibhate, Avachat) were deposed on ANDA amendments and FDA correspondence.
• 2019-07-08 and 2019-07-15: Sun filed letter-motions to compel (D.E. 71, D.E. 76) seeking post-complaint Lupin emails relating to ANDA amendments and FDA correspondence, plus sanctions.
• 2019-07-18: Lupin's opposition (D.E. 81, Hill Wallack LLP, Eric Abraham, with Rakoczy Molino Mazzochi Siwik LLP) argued the request was a "fishing expedition" because infringement is properly measured by the ANDA specification (Bayer v. Elan; Alcon v. Barr), and that Sun was improperly hunting for evidence of objective indicia (unexpected results, commercial success).
• Expert discovery: opening reports were due 2019-07-31 (Lupin sought a two-week extension to 2019-08-14); rebuttal 2019-08-28; Lupin's reply on objective indicia 2019-09-20. Dispositive motions were then due 2019-11-15, with trial originally set for April 2020.
• 2019-10-25: Sun moved to strike the report of James T. Carmichael, Lupin's former-PTO-examiner expert (ECF No. 121).
• 2019-11-18: Lupin cross-moved to preclude all testimony about the examiner's search history (ECF No. 129).
• 2021-01-08: Lupin moved to exclude portions of Sun's expert Dr. Olejnik's testimony on gelation, anticipation, and obviousness (ECF No. 165).

The Daubert ruling — ECF No. 185 (filed 2021-03-08; reported at 2021 WL ____ / Law.com pub. 2021-03-19), three weeks before trial. The court:

• Granted Sun's motion to strike the Carmichael Report in its entirety — testimony about PTO "policies, procedures, defects, pressures, and incentives," and about what the examiner subjectively reviewed, is inadmissible (citing Comcast v. Sprint); Sun had also disclaimed any intent to argue the examiner "likely reviewed" Bowman I.
• Granted in part Lupin's cross-motion (precluding examiner search-history/state-of-mind testimony), and
• Denied in part Lupin's motion to exclude Dr. Olejnik.

The net effect was to strip Lupin's inequitable-conduct defense of its prosecution-practice expert going into trial, and to narrow the indefiniteness/obviousness fight to the technical experts (Dr. Olejnik and Dr. Hanes) and Dr. Bowman himself.

The 2020 settlement that failed. Both the court's opinion and the docket reflect that the parties "attempted to settle in 2020" (ECF No. 145) but "were unable to do so" (ECF No. 155). Aggregators accordingly show the docket as "terminated" 2020-02-02/03 and ParagraphFour labels the case "settled and dismissed 2/3/20." Read against the record, that appears to be an administrative closure during a failed settlement/30-day dismissal window that was later reopened, not a final disposition. I could not retrieve the underlying 2020 order to confirm its terms — treat the 2020-02-02 date as a docket-management artifact, not a settlement.

3. Claim construction (Markman)

There was no separate Markman opinion or hearing on this docket that I could locate. The dispositive claim-construction dispute was instead resolved inside the post-trial findings: whether the viscosity range is measured only by the methods disclosed in the specification, and whether "spin time" is an implicit claim limitation. The court held that "when a patent specifies a testing method, particularly for a non-Newtonian thixotropic fluid such as BromSite, … the method in the patent is the only salient comparator for purposes of determining infringement, unless it is identifiable as part of a POSA's general background knowledge based on a convention in the field or standard industry practice" (ECF No. 244, citing Marine Polymer v. HemCon, SciMed Life, Cultor). That construction drove both the non-infringement and indefiniteness holdings. Note the construction was case-dispositive yet never issued as a standalone order — a structural feature worth flagging if you are assessing the case's precedential footprint.

4. Trial and the September 30,

I'll search several angles to find press coverage of this case.

Press and trade coverage of Sun Pharmaceutical Industries Ltd. v. Lupin Ltd. (D.N.J. 3:18-cv-02213)

Coverage of the ruling is thin but real, and concentrated in legal/trade trade press. The most substantive contemporaneous reporting came from Law360, whose case page carries a September 30, 2021 article headlined "Sun Pharma's Eye Pain Patent Invalidated," reporting that a New Jersey federal judge invalidated Sun's patent on BromSite "finding on Thursday that the patent was obvious in light of an earlier patent." Life Sciences IP Review also flagged the decision on 5 October 2021, noting that "a New Jersey court has invalidated a Sun Pharmaceuticals patent related to its anti-inflammatory eye drops BromSite in an infringement suit against generic drug manufacturer Lupin Pharmaceuticals." Neither outlet divulged damages figures — none were awarded, since this was a bench trial on infringement/validity, not a damages trial. The fullest technical account is not journalism but law-firm analysis: Robins Kaplan's GENERICally Speaking Hatch-Waxman Bulletin summarized the September 30, 2021 opinion (2021 WL 4473411) as holding the ANDA product does not literally infringe (Sun's viscosity testing was unreliable because it did not report spin time), and that the '999 patent was nonetheless invalid as obvious over the Bowman reference and indefinite under Nautilus for failing to specify a spin-time parameter, while rejecting Lupin's inequitable-conduct theory against Dr. Lyle Bowman.

The settlement and vacatur drew a second, brief round of coverage. Law360 reported on February 8, 2022 in "Sun Pharma, Lupin Agree To Drop Eye Pain Patent Dispute" that Sun "agreed to drop a patent lawsuit against rival Lupin Pharmaceuticals over a branded treatment to prevent pain from eye surgery, while getting a New Jersey federal judge to toss an earlier ruling that invalidated Sun's patent at the heart of the case" (a syndicated copy of that Tiffany Hu story is also republished here). No outlet I found reported the terms of the settlement, and none reported any payment, license, or launch-date concession — consistent with the docket, where dismissal with prejudice (ECF No. 260–261) followed the February 8, 2022 vacatur order (ECF No. 259), with no public terms.

The commercial aftermath — Lupin's generic launch — generated the widest, if least legally substantive, coverage. Lupin's own press release (February 6, 2024) announced FDA approval of ANDA 211239 for bromfenac ophthalmic solution 0.075%, stating Lupin "is the exclusive first-to-file for this product," would manufacture at its Pithampur facility, and that the RLD BromSite "had estimated annual sales of USD 15 million in the U.S. (IQVIA MAT December 2023)" — the only hard number reported anywhere in the coverage. That $15 million figure was repeated verbatim by Drug Store News, Business Standard (Feb 14, 2024), ET HealthWorld (Feb 13, 2024), and EyeWorld Weekly. Notably, Optum Rx's new-generics bulletin reported a detail absent from the court record and from Lupin's release: that Lupin launched an AB-rated generic on February 13, 2024 and "Sun launched an authorized brand alternative of BromSite."

Two caveats on sourcing. First, I found no Reuters, Bloomberg Law, IPWatchdog, Patently-O, Ars Technica, JD Supra, or general-interest coverage of this case; the reporting ecosystem is essentially Law360 plus one IP trade outlet plus Indian pharma trade press, so any claim that the case was treated as a landmark is unsupported — it was covered as a routine ANDA outcome. Second, the secondary databases disagree with the docket on timing: ParagraphFour's entry lists the case as "Settled and dismissed 2/3/20" (an apparent data error — the docket shows a 2020 settlement attempt failed, ECF No. 155, with dismissal only in February 2022), and DrugPatentWatch lists two different termination dates (2020-02-02 and 2021-09-30) for the same docket. The court record — September 30, 2021 opinion at ECF No. 244, vacated February 8, 2022, dismissal with prejudice thereafter — should be preferred over these aggregators.

Sources

• NOT FOR PUBLICATION
• Lupin further argues that a POSA would have understood that bromfenac and diclofenac have similar properties, are subject to sim...
• Sun Pharma Global Fze v. Lupin Ltd. - Sun Pharma Global Fze v. Lupin Ltd.
• Opinion – #244 in SUN PHARMACEUTICAL INDUSTRIES LTD. v. LUPIN LIMITED (D.N.J., 3:18-cv-02213) – CourtListener.com - 🚀 CourtListener is now available in ChatGPT
• BROMSITE drug patent trials and PTAB cases for biologic and small molecule drugs - Last Updated: March 18, 2026
• SUN PHARMA GLOBAL FZE et al v. LUPIN LIMITED et al, No. 3:2018cv02213 - Document 185 (D.N.J. 2021) - SUN PHARMA GLOBAL FZE et al v. LUPIN LIMITED et al, No. 3:2018cv02213 - Document 185 (D.N.J. 2021)
• Seal Document – #99 in SUN PHARMACEUTICAL INDUSTRIES LTD. v. LUPIN LIMITED (D.N.J., 3:18-cv-02213) – CourtListener.com - SUN PHARMACEUTICAL INDUSTRIES LTD. v. LUPIN LIMITED
• Decision: Sun Pharma Global FZE v. Lupin Ltd.| Law.com
• SUN PHARMACEUTICAL INDUSTRIES LTD. v. LUPIN LIMITED, 3:18-cv-02213 - CourtListener.com - SUN PHARMACEUTICAL INDUSTRIES LTD. v. LUPIN LIMITED (3:18-cv-02213)
• ANDA 211239
• SUN PHARMA GLOBAL FZE et al v. LUPIN LIMITED et al, No. 3:2018cv02213 - Document 244 (D.N.J. 2021) - SUN PHARMA GLOBAL FZE et al v. LUPIN LIMITED et al, No. 3:2018cv02213 - Document 244 (D.N.J. 2021)
• SUN PHARMA GLOBAL FZE et al v

I'll research this thoroughly, starting with the opinion's appearance block and docket entries.

Interesting — the signature block on ECF No. 260 needs verification, since it may conflict with the earlier section's attribution. Let me pull primary sources.

The docket shows a shift in counsel over time. Let me pull the actual filings to verify who signed for Sun at each stage.

Counsel of Record for Plaintiffs — Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc. (and, at filing, Sun Pharma Global FZE)

Bottom line: Sun's team was a two-firm structure — Rivkin Radler LLP as national/lead patent counsel and Hill Wallack LLP (Princeton, N.J.) as New Jersey local counsel — with a possible later addition of **Rakoczy Molino Mazzochi Si

I'll research Lupin's counsel of record across the docket, opinions, and firm sources.

Counsel of Record for the Defendants (Lupin Ltd. and Lupin Pharmaceuticals, Inc.)

Bottom line. Lupin's defense was run by a two-firm team in the classic D.N.J. split: an out-of-state Hatch-Waxman boutique as principal/lead counsel (admitted pro hac vice) and a Princeton, N.J. general-practice firm as local counsel. Both defendants — Lupin Ltd. (Mumbai) and Lupin Pharmaceuticals, Inc. (Baltimore) — were represented jointly by the same team; no separate counsel appeared for either entity, and I found no in-house Lupin attorney entering an appearance.

Principal / lead counsel — Rakoczy Molino Mazzochi Siwik LLP (Chicago)

Signature block, ECF No. 99 (joint motion to seal, filed Sept. 2019), captioned "Attorneys for Defendants/Counterclaim-Plaintiffs, Lupin Ltd. and Lupin Pharmaceuticals, Inc.":

Firm address in this matter: 6 West Hubbard Street, Suite 500, Chicago, IL 60654, (312) 527-2157 (firm email domain rmmslegal.com). The firm also appears in some filings as "RMMS Legal."

Local counsel — Hill Wallack LLP (Princeton, N.J.)

Hill Wallack filed Lupin's July 18, 2019 discovery opposition (D.E. 81) on firm letterhead, and its attorneys are the ECF filers on Lupin's behalf in this docket:

Office address used in this case: 21 Roszel Road, Princeton, New Jersey 08540, (609) 924-0808. (Note that Hill Wallack's filings in other matters list 202 Carnegie Center, Princeton — the firm has used more than one Princeton address; the Roszel Road address is the one in this docket.)

What I could not verify — read before relying

1. No appearances section in the opinion. The Sept. 30, 2021 opinion (ECF No. 244) does not carry a counsel/appearances block, which is typical for D.N.J. published opinions. My counsel list is therefore built from signed filings (ECF Nos. 81, 99, 185 and the Abraham Declaration exhibits), not from the judgment or opinion.
2. Trial counsel of record for the March 2021 bench trial is not confirmed from a primary source. I did not retrieve the trial transcripts, and the Law360 coverage I could access did not name the attorneys arguing. Whether Rakoczy or Molino delivered the trial argument should be treated as probable but unconfirmed.
3. The CourtListener docket's attorney-of-record roster was not retrievable in this session (the docket page text I could pull showed individual entries and ECF filers, not the consolidated "Attorneys" pane). PACER's "Attorneys" tab for 3:18-cv-02213 would settle the full list, including any attorney who appeared and later withdrew.
4. Deanne M. Mazzochi is a name partner of Rakoczy Molino Mazzochi Siwik and a frequent Lupin counsel in other ANDA cases, but I found no document placing her on this docket; do not list her as counsel here without a PACER check.
5. Post-dismissal status. Because the case ended by stipulated dismissal with prejudice (ECF No. 261) rather than judgment, there was no appellate appearance and no Federal Circuit counsel to report. I also did not confirm whether any of the named attorneys have since changed firms; the firm/office affiliations above reflect the record as of the 2019–2021 filings.
6. Nothing here is sealed. Counsel's identities are public in the filings cited; the sealed materials in this case (D.E. 99 series and related) concern confidential ANDA/discovery content, not appearances.

One cross-reference flag

The earlier case-overview section describes Lupin's July 18, 2019 opposition as filed by "Hill Wallack LLP, Eric Abraham, with Rakoczy Molino Mazzochi Siwik LLP." That is consistent with everything I found (the D.E. 81 PDF is on Hill Wallack letterhead arguing for Lupin; the D.E. 99 signature block lists the Rakoczy firm as "Attorneys for Defendants/Counterclaim-Plaintiffs"). Note, however, that the OCR of the D.E. 99 caption block interleaves the two sides' attorney blocks in a way that could mislead a reader into attributing Eric I. Abraham to Sun. He is Lupin's local counsel; Sun's papers in this docket were handled by separate counsel, not Hill Wallack.

Sources: ECF No. 99 (Sept. 2019 joint motion to seal) via CourtListener RECAP, https://storage.courtlistener.com/recap/gov.uscourts.njd.[366742](/patent/366742)/gov.uscourts.njd.366742.99.0.pdf; ECF No. 81 (Lupin opposition, July 18, 2019), https://archive.org/download/gov.uscourts.njd.366742/gov.uscourts.njd.366742.81.0.pdf; CourtListener docket, https://www.courtlistener.com/docket/6668689/sun-pharmaceutical-industries-ltd-v-lupin-limited/; Janssen Prods., L.P. v. Lupin Ltd., Nos. 2014-1842/-1843 (Fed. Cir.) brief and caption, https://storage.courtlistener.com/recap/gov.uscourts.cafc.14-1842.42.0.pdf; N.D. Cal. No. 4:09-cv-05587-PJH filings naming Rakoczy, Molino and Pernic Waldron for Lupin.